Impact of ribavirin dose on retreatment of chronic hepatitis C patients

Table 1 Baseline characteristics n (%)

	All patients (n = 62)
Male gender	45 (72.6)
Mean age, yr ± SD	52 ± 9
Mean weight, kg ± SD	76 ± 14
Mean BMI, kg/m2± SD	26 ± 4
Abnormal ALT	54 (90)
Abnormal GGT	36 (67)
Mean hemoglobin, g/dL ± SD	14.8 ± 1.5
HCV RNA
> 600 000 IU/mL	11 (28)
METAVIR fibrosis score
F2	20 (34)
F3	11 (19)
F4	23 (39)
Steatosis
< 5%	13 (21)
5%-30%	23 (37)
> 30%	26 (42)

BMI: Body mass index; ALT: Alanine aminotransferase; GGT: γ-glutamyl transferase; HCV: Hepatitis C virus.

Table 2 Treatment characteristics

	No. of patients, n (%)	SVR (%)
Overall population	62 (100)	42
Type of PEG-IFN (retreatment)
PEG-IFN-α2a	43 (69)	40
PEG-IFN-α2b	19 (31)	47
RBV ≥ 13.3 mg/kg per day	34 (54)	35
RBV ≥ 15.2 mg/kg per day	10 (16)	70
Treatment duration 24 wk longer than previous course	31 (51)	53
Patients with RBV ≥ 15.2 mg/kg per day and 24 wk longer duration	6 (10)	67

Sustained virological response (SVR) according to different types of pegylated interferon (PEG-IFN), dose of ribavirin (RBV) and duration of therapy.